Lori Ann Cox

NPI: 1437229143
Total Payments
$2.2M
2024 Payments
$339,085
Companies
2
Transactions
247

Payment Breakdown by Category

Consulting$2.2M (98.7%)
Other$14,940 (0.7%)
Research$13,180 (0.6%)

Payments by Nature

Nature of Payment Amount Transactions Share
Consulting Fee $2.2M 223 98.7%
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $14,940 11 0.7%
Unspecified $13,180 13 0.6%

Payments by Type

General
$2.2M
234 transactions
Research
$13,180
13 transactions

Top Paying Companies

Company Total Records Latest Year
PFIZER INC. $1.9M 232 $0 (2021)
Janssen Research & Development, LLC $349,334 15 $0 (2024)

Payment History by Year

Year Amount Transactions Top Company
2024 $339,085 13 Janssen Research & Development, LLC ($339,085)
2021 $2,100 5 PFIZER INC. ($2,100)
2020 $522,352 59 PFIZER INC. ($522,352)
2019 $449,207 60 PFIZER INC. ($449,207)
2018 $458,153 55 PFIZER INC. ($458,153)
2017 $467,533 55 PFIZER INC. ($457,284)

All Payment Transactions

247 individual payment records from CMS Open Payments — Page 1 of 10

Date Company Product Nature Form Amount Type
12/19/2024 Janssen Research & Development, LLC TREMFYA (Drug) Consulting Fee Cash or cash equivalent $11,497.50 General
Category: Immunology
12/06/2024 Janssen Research & Development, LLC TREMFYA (Drug) Consulting Fee Cash or cash equivalent $8,395.00 General
Category: Immunology
12/02/2024 Janssen Research & Development, LLC TREMFYA (Drug) Consulting Fee Cash or cash equivalent $20,987.50 General
Category: Immunology
11/06/2024 Janssen Research & Development, LLC TREMFYA (Drug) Consulting Fee Cash or cash equivalent $10,402.50 General
Category: Immunology
10/31/2024 Janssen Research & Development, LLC TREMFYA (Drug) Consulting Fee Cash or cash equivalent $10,585.00 General
Category: Immunology
10/22/2024 Janssen Research & Development, LLC TREMFYA (Drug) Consulting Fee Cash or cash equivalent $16,607.50 General
Category: Immunology
10/10/2024 Janssen Research & Development, LLC TREMFYA (Drug) Consulting Fee Cash or cash equivalent $9,672.50 General
Category: Immunology
10/03/2024 Janssen Research & Development, LLC TREMFYA (Drug) Consulting Fee Cash or cash equivalent $7,847.50 General
Category: Immunology
09/26/2024 Janssen Research & Development, LLC TREMFYA (Drug) Consulting Fee Cash or cash equivalent $44,347.50 General
Category: Immunology
09/23/2024 Janssen Research & Development, LLC TREMFYA (Drug) Consulting Fee Cash or cash equivalent $9,490.00 General
Category: Immunology
08/19/2024 Janssen Research & Development, LLC TREMFYA (Drug) Consulting Fee Cash or cash equivalent $96,360.00 General
Category: Immunology
06/10/2024 Janssen Research & Development, LLC TREMFYA (Drug) Consulting Fee Cash or cash equivalent $20,075.00 General
Category: Immunology
05/03/2024 Janssen Research & Development, LLC TREMFYA (Drug) Consulting Fee Cash or cash equivalent $72,817.50 General
Category: Immunology
09/13/2021 PFIZER INC. In-kind items and services $330.00 Research
Study: RITLECITINIB CLINICAL PUBLICATION PROGRAM
09/10/2021 PFIZER INC. In-kind items and services $330.00 Research
Study: RITLECITINIB CLINICAL PUBLICATION PROGRAM
09/07/2021 PFIZER INC. In-kind items and services $330.00 Research
Study: RITLECITINIB CLINICAL PUBLICATION PROGRAM
08/18/2021 PFIZER INC. In-kind items and services $330.00 Research
Study: RITLECITINIB CLINICAL PUBLICATION PROGRAM
06/02/2021 PFIZER INC. In-kind items and services $780.00 Research
Study: RITLECITINIB CLINICAL PUBLICATION PROGRAM
12/27/2020 PFIZER INC. Consulting Fee Cash or cash equivalent $7,766.63 General
12/06/2020 PFIZER INC. Consulting Fee Cash or cash equivalent $10,608.08 General
11/29/2020 PFIZER INC. Consulting Fee Cash or cash equivalent $8,334.92 General
11/22/2020 PFIZER INC. Consulting Fee Cash or cash equivalent $10,418.65 General
11/15/2020 PFIZER INC. Consulting Fee Cash or cash equivalent $11,271.09 General
11/12/2020 PFIZER INC. In-kind items and services $3,200.00 Research
Study: RITLECITINIB CLINICAL PUBLICATION PROGRAM
11/10/2020 PFIZER INC. In-kind items and services $780.00 Research
Study: RITLECITINIB CLINICAL PUBLICATION PROGRAM

Research Studies & Clinical Trials

Study Name Company Amount Records
RITLECITINIB CLINICAL PUBLICATION PROGRAM PFIZER INC. $10,840 10
INFLAMIMMUNO CLINICAL PUBLICATION PROGRAM PFIZER INC. $1,560 2
JAK 3TEC CLINICAL PUBLICATION PROGRAM PFIZER INC. $780.00 1

About Lori Ann Cox

Lori Ann Cox is a Rheumatology healthcare provider based in New Brunswick, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/09/2006. The National Provider Identifier (NPI) number assigned to this provider is 1437229143.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Lori Ann Cox has received a total of $2.2M in payments from pharmaceutical and medical device companies, with $339,085 received in 2024. These payments were reported across 247 transactions from 2 companies. The most common payment nature is "Consulting Fee" ($2.2M).

Practice Information

  • Specialty Rheumatology
  • Location New Brunswick, NJ
  • Active Since 11/09/2006
  • Last Updated 02/07/2008
  • Taxonomy Code 207RR0500X
  • Entity Type Individual
  • NPI Number 1437229143

Products in Payments

  • TREMFYA (Drug) $339,085

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Rheumatology Doctors in New Brunswick